Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06466187 | A Study of SGN-MesoC2 in Advanced Solid Tumors | PHASE1 | ACTIVE NOT_RECRUITING | 19 | — | — | Aug 2, 2024 | May 1, 2029 | Jan 12, 2026 | 21 | United States, Canada |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Frequency of dose modifications (eg, dose delay, treatment interruptions, dose reductions and treatment discontinuations) due to AEs
Incidence of dose-limiting toxicities (DLTs)
| Arm | Type | Description |
|---|---|---|
| PF-08052666 | EXPERIMENTAL | PF-08052666 monotherapy |
| Name | Type | Description |
|---|---|---|
| PF-08052666 | DRUG | Given into the vein (IV; intravenously) |
Inclusion Criteria: * Aged 18 years or older. * Histologically- or cytologically-confirmed metastatic or locally advanced unresectable platinum-resistant ovarian cancer, NSCLC, pancreatic ductal adenocarcinoma, endometrial cancer, colorectal cancer, or mesothelioma, who have relapsed or progressed ...